Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 1 of 1

GlaxoSmithKline (GSK), London headquarters pictured, has been fined £37.6m for entering into deals that deliberately delayed the entry of generic versions of its blockbuster antidepressant Seroxat (paroxetine) into the UK market

GSK agreed to pay £50m to suppliers of generic medicines to delay market entry of their paroxetine products

Source  Ian Wilson / Wikimedia Commons